Brief: Adial Pharmaceuticals Signs An Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici For Europe Which Anticipates Nearly $60 Million In Potential Royalties And Milestones Upon Execution Of A Definitive Agreement
03/03/2026 13:18
March 3 (Reuters) - Adial Pharmaceuticals Inc ADIL.O: ADIAL PHARMACEUTICALS SIGNS AN EXCLUSIVE AD04 COLLABORATION FRAMEWORK WITH MOLTENI FARMACEUTICI FOR EUROPE WHICH ANTICIPATES NEARLY $60 MILLION IN POTENTIAL ROYALTIES AND MILESTONES UPON EXECUTION OF A DEFINITIVE AGREEMENT ADIAL PHARMACEUTICALS INC: ENGAGING WITH POTENTIAL COMMERCIAL PARTNERS IN UNITED STATES, TO INITIATE ITS PIVOTAL PHASE 3 PROGRAM IN NEAR TERM Source text: ID:nGNXbhXDHz Further company coverage: ADIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)